glp-1 drugs with least side effects Managing of Receptor Agonists – Transformation Weight Control GLP-1 Agonists: Using Semaglutide, Tirzepatide,

Wegovy contains semaglutide and is approved specifically for weight management in the UK (16), while Mounjaro acts on two hormone pathways (GLP-1 and GIP) and has demonstrated greater average weight loss in head-to-head clinical trials (17)

Consequently, once-daily subcutaneous administration of liraglutide 3.0 mg was developed for the treatment of obesity [21] and once-weekly subcutaneous administration of semaglutide 2.4 mg is currently being investigated in phase III trials for this indication [22]

However, it is also expressed, to differing degrees, in the kidneys, adrenal glands, gastrointestinal tract, pancreas, adipose tissue, and heart (Svoboda et al

Mullins RJ, Mustapic M, Chia CW, Carlson O, Gulyani S, Tran J, et al